Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 623

1.

The impact of the model for end-stage liver disease (MELD) on liver transplantation in one center in Brazil.

Freitas AC, Itikawa WM, Kurogi AS, Stadnik LG, Parolin MB, Coelho JC.

Arq Gastroenterol. 2010 Jul-Sep;47(3):233-7.

2.
3.

A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system.

Piscaglia F, Camaggi V, Ravaioli M, Grazi GL, Zanello M, Leoni S, Ballardini G, Cavrini G, Pinna AD, Bolondi L.

Liver Transpl. 2007 Jun;13(6):857-66.

4.

Consequences of the implementation of the Model for End-stage Liver Disease system for liver allocation in Brazil.

Pestana RC, Baracat EI, Massarollo PC, Pereira LA, Szutan LA.

Transplant Proc. 2013 Jul-Aug;45(6):2111-4. doi: 10.1016/j.transproceed.2012.11.007. Epub 2013 Jun 5.

PMID:
23747144
5.

Living donor liver transplantation in adults in the MELD era in Germany--a multi-center retrospective analysis.

Settmacher U, Götz M, Rahmel A, Bärthel E, Schlitt H, Puhl G, Broering D, Lehner F, Fischer L, Paul A, Schmidt J, Nadalin S, Obed A, Heise M.

Transpl Int. 2011 Sep;24(9):904-11. doi: 10.1111/j.1432-2277.2011.01283.x. Epub 2011 Jun 11.

6.

Multicentric evaluation of model for end-stage liver disease-based allocation and survival after liver transplantation in Germany--limitations of the 'sickest first'-concept.

Weismüller TJ, Fikatas P, Schmidt J, Barreiros AP, Otto G, Beckebaum S, Paul A, Scherer MN, Schmidt HH, Schlitt HJ, Neuhaus P, Klempnauer J, Pratschke J, Manns MP, Strassburg CP.

Transpl Int. 2011 Jan;24(1):91-9. doi: 10.1111/j.1432-2277.2010.01161.x. Epub 2010 Sep 3.

7.

Model for End-Stage Liver Disease (MELD) score system to evaluate patients with viral hepatitis on the waiting list: better than the Child-Turcotte-Pugh (CTP) system?

Cuomo O, Perrella A, Arenga G.

Transplant Proc. 2008 Jul-Aug;40(6):1906-9. doi: 10.1016/j.transproceed.2008.05.072.

PMID:
18675085
8.

Survival on waiting list for liver transplantation before and after introduction of the model for end-stage liver disease score.

Tenório AL, Macedo FI, Miranda LE, Fernandes JL, da Silva CM, Neto OL, Lacerda CM.

Transplant Proc. 2010 Mar;42(2):407-11. doi: 10.1016/j.transproceed.2010.01.005.

PMID:
20304152
9.

[The application of MELD score in patients submitted to liver transplantation: a retrospective analysis of survival and the predictive factors in the short and long term].

Boin Ide F, Leonardi MI, Udo EY, Sevá-Pereira T, Stucchi RS, Leonardi LS.

Arq Gastroenterol. 2008 Oct-Dec;45(4):275-83. Portuguese.

10.

Analysis of the survival of cirrhotic patients enlisted for liver transplantation in the pre- and post-MELD era in southern Brazil.

Mattos ÂZ, Mattos AA, Sacco FK, Hoppe L, Oliveira DM.

Arq Gastroenterol. 2014 Jan-Mar;51(1):46-52.

11.

Aetiology of cirrhosis of the liver has an impact on survival predicted by the Model of End-stage Liver Disease score.

Angermayr B, Luca A, König F, Bertolini G, Ploner M, Gridelli B, Ulbrich G, Reiberger T, Bosch J, Peck-Radosavljevic M.

Eur J Clin Invest. 2009 Jan;39(1):65-71. doi: 10.1111/j.1365-2362.2008.02063.x.

PMID:
19087131
12.

Liver transplantation for hepatocellular carcinoma: the MELD impact.

Sharma P, Balan V, Hernandez JL, Harper AM, Edwards EB, Rodriguez-Luna H, Byrne T, Vargas HE, Mulligan D, Rakela J, Wiesner RH.

Liver Transpl. 2004 Jan;10(1):36-41.

13.

Improved outcome of adult recipients with a high model for end-stage liver disease score and a small-for-size graft.

Yi NJ, Suh KS, Lee HW, Shin WY, Kim J, Kim W, Kim YJ, Yoon JH, Lee HS, Lee KU.

Liver Transpl. 2009 May;15(5):496-503. doi: 10.1002/lt.21606.

14.

Impact of model for end-stage liver disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis.

Cucchetti A, Ercolani G, Vivarelli M, Cescon M, Ravaioli M, La Barba G, Zanello M, Grazi GL, Pinna AD.

Liver Transpl. 2006 Jun;12(6):966-71.

15.

The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study.

Murillas J, Rimola A, Laguno M, de Lazzari E, Rascón J, Agüero F, Blanco JL, Moitinho E, Moreno A, Miró JM; ESLD-HIV Working Group Investigators.

Liver Transpl. 2009 Sep;15(9):1133-41. doi: 10.1002/lt.21735.

16.

A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list.

Vitale A, Volk ML, De Feo TM, Burra P, Frigo AC, Ramirez Morales R, De Carlis L, Belli L, Colledan M, Fagiuoli S, Rossi G, Andorno E, Baccarani U, Regalia E, Vivarelli M, Donataccio M, Cillo U; Liver Transplantation North Italy Transplant program (NITp) working group.

J Hepatol. 2014 Feb;60(2):290-7. doi: 10.1016/j.jhep.2013.10.010. Epub 2013 Oct 23. Erratum in: J Hepatol. 2014 Jun;60(6):1336. Multiple investigator names added.

PMID:
24161408
17.

Testing liver allocation in São Paulo, Brazil: the relationship of model for end-stage liver disease implementation with a reduction in waiting-list mortality.

Salvalaggio PR, Afonso RC, Pereira LA, Ferraz-Neto BH.

Transplant Proc. 2012 Oct;44(8):2283-5. doi: 10.1016/j.transproceed.2012.07.045.

PMID:
23026574
19.

Impact of MELD score implementation on liver allocation: experience at a Brazilian center.

da Silva Machado AG, de Medeiros Fleck A Jr, Marroni C, Zanotelli ML, Cantisani G, de Mello Brandão AB.

Ann Hepatol. 2013 May-Jun;12(3):440-7.

20.

Analysis of Model for End-Stage Liver Disease (MELD) score in a liver transplantation waiting list.

Ferraz-Neto BH, Hidalgo R, Thomé T, Melo VA Jr, Lobue A, Zurstrassen MP, Moraes JM Jr, Meira-Filho SP, Rezende MB, Fonseca LE, Pandullo FL, Soeiro FS, Afonso RC.

Transplant Proc. 2007 Oct;39(8):2511-3.

PMID:
17954160

Supplemental Content

Support Center